Haemonetics (HAE) Invested Capital (2010 - 2026)

Haemonetics' Invested Capital history runs 17 years deep, the most recent figure standing at $5.0 million for Q1 2026.

• On a quarterly basis, Invested Capital fell 98.35% year-over-year to $5.0 million in Q1 2026; TTM through Mar 2026 was $918.0 million, a 187.63% increase from a year earlier, with the FY2026 full-year figure at $5.0 million, down 98.35% from the prior year.
• Invested Capital fell to $5.0 million in Q1 2026 per HAE's latest filing, from $304.7 million in the prior quarter.
• Across five years, Invested Capital topped out at $304.7 million in Q4 2025 and bottomed at $5.0 million in Q1 2026.
• The 5-year median for Invested Capital is $13.6 million (2023), against an average of $96.3 million.
• Across the five-year window, Invested Capital surged 5904.85% in 2025 and plunged 98.35% in 2026, its largest moves.
• Year by year, Invested Capital stood at $9.9 million in 2022, then jumped by 38.06% to $13.7 million in 2023, then tumbled by 63.05% to $5.1 million in 2024, then jumped by 5904.85% to $304.7 million in 2025, then plunged by 98.35% to $5.0 million in 2026.
• Per Business Quant, the three latest HAE Invested Capital figures stand at $5.0 million (Q1 2026), $304.7 million (Q4 2025), and $304.3 million (Q3 2025).